Ocrevus ocrelizumab

The single biggest commercial leverage point is the "crap gap" window (months 4-6 between infusions) where symptom return drives switching to Kesimpta; a peer-to-peer reassurance program at that exact moment is the highest-ROI retention play available.

• The twice-yearly IV schedule is Ocrevus's most-cited adherence driver, but the 'crap gap' of symptom return before the next infusion is the top switching trigger and the primary unmet emotional need in the corpus.
• Infection vulnerability (UTIs, shingles, respiratory illness, COVID) dominates long-term safety anxiety far more than infusion reactions, which patients learn to manage with premedication and accept as a one-day inconvenience.
• Insurance prior-authorization friction and out-of-pocket cost anxiety are discussed in nearly every initiation thread, functioning as a parallel barrier to starting or continuing treatment that rivals clinical concerns.
• An emerging FDA PPMS efficacy reassessment and a new Lancet higher-dose null finding are seeding patient-level doubt about long-term value, especially among women with PPMS, a segment needing proactive medical communication.